Health-related quality of life (HRQoL) was measured using the EQ-5D questionnaire [22] at baseline and after 24 weeks of therapy.Go to context

The proportion of patients reaching HbA1c<7.0% [53 mmol/mol] with insulin detemir ± OGLDs was ∼30%, irrespective of prestudy therapy; similar to that reported for the entire A1chieve study cohort (31.8%) [7] and for basal insulin analogue therapy in RCTs [25,26].Go to context

The proportion of patients reaching HbA1c<7.0% [53 mmol/mol] with insulin detemir ± OGLDs was ∼30%, irrespective of prestudy therapy; similar to that reported for the entire A1chieve study cohort (31.8%) [7] and for basal insulin analogue therapy in RCTs [25,26].Go to context

The proportion of patients reaching HbA1c<7.0% [53 mmol/mol] with insulin detemir ± OGLDs was ∼30%, irrespective of prestudy therapy; similar to that reported for the entire A1chieve study cohort (31.8%) [7] and for basal insulin analogue therapy in RCTs [25,26].Go to context

Regionally, both the poor level of glycaemic control at baseline and the magnitude of improvement were remarkably consistent.Go to context

Interestingly, in the entire A1chieve study population, although no clinically significant weight change was reported, a larger range was seen (−0.8 and +0.9kg) [7].Go to context

Interestingly, in the entire A1chieve study population, although no clinically significant weight change was reported, a larger range was seen (−0.8 and +0.9kg) [7].Go to context

The A1chieve study, by nature of its design, has a number of limitations that must be considered when interpreting the data [7].Go to context

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Crossref.

Significant improvements in all measures of glycaemic control were seen regardless of prior insulin regimen, human or analogue, which supports previous findings from a clinical practice [19].Go to context

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyCrossref.